166952-78-9Relevant articles and documents
Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities
Zbancioc, Ana Maria,Miron, Anca,Tuchilus, Cristina,Rotinberg, Pincu,Mihai, Cosmin Teodor,Mangalagiu, Ionel I.,Zbancioc, Gheorghita
, p. 476 - 483 (2014/06/23)
Herein we report a feasible study concerning the design, syntheses and in vitro antimicrobial and antitumoral activities of some novel compounds with dihydroxyacetophenone (DA) moiety. An efficient and general method for the preparation of diazine with dihydroxyacetophenone (DDA) skeleton under conventional thermal heating (TH), microwave (MW) and ultrasounds (US) irradiation is presented. Antimicrobial and antitumoral tests prove that some dihydroxyacetophenone compounds (the brominated derivatives BrDA 3) have a significant biological activity. It is also to be pointed out that, basically all the dihydroxyacetophenone derivatives proved to have a powerful antibacterial activity against drug resistant Gram-negative strain Pseudomonas aeruginosa ATCC 27853. Of particular interest could be the excellent antibacterial activity of our dihydroxyacetophenone compounds against drug resistant Gram-negative strain Pseudomonas aeruginosa.
Guanidino substituted isoindolones as novel glycoprotein IIb-IIIa receptor antagonists
Lal, Bansi,Gangopadhyay, Ashok K.,Jagtap,Tanpure, Rajendra,Rao,Gupte, Ravindra D.,Subbarayan,Asudani, Gope
, p. 1815 - 1832 (2008/09/18)
Design and synthesis of a novel potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonist based on isoindolone skeleton has been described. This scaffold has been derived from earlier reported pseudopeptides. Synthesis by a novel route has been achieved. Few molecules show very potent in vitro activity. Further identification of probable additional hydrogen bond donor site has been described.
Heterocyclic derivatives
-
, (2008/06/13)
Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.